NEWS AND EVENTS
NEWS AND EVENTS
Sanifit highlights publication of “50 Key Questions on Calciphylaxis”
Palma, Spain and San Diego, USA, 21 November, 2018 – Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company focused on treatments for calcification disorders, is pleased to note the publication of ’50 Key Questions on Calciphylaxis in Chronic Kidney Disease’ by Dr José Vicente Torregrosa and Dr David Cucchiari, the printing of which was sponsored by Sanifit. […]
Data from first in-human clinical trial of SNF472 in haemodialysis patients published in British Journal of Clinical Pharmacology
Palma, Spain and San Diego, USA, 23 October, 2018 – Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company focused on treatments for calcification disorders, today announces that data from a phase I study assessing the safety and tolerability of its lead drug candidate SNF472 in haemodialysis patients has been published in the British Journal of Clinical […]
Sanifit announces completion of enrollment in CaLIPSO – its Phase 2b Study for the Treatment of Cardiovascular Calcification in End-Stage-Renal-Disease Patients on Haemodialsis
Palma, Spain and San Diego, USA, August 6th, 2018 – Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company focused on treatments for calcification disorders, today announced the completion of enrollment of its Phase 2b CaLIPSO clinical trial investigating Sanifit’s lead candidate SNF472, for the treatment of cardiovascular calcification (CVC) in end-stage-renal-disease (ESRD) patients on haemodialysis (HD). […]
Sanifit to present at the 2018 European Biotech Investor Day in New York City
Palma, Spain and San Diego, USA, July 17, 2018 – Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company focused on treatments for calcification disorders, will present at the European Biotech Investor Day in NYC, organized by Solebury Trout, Goodwin LLC and Nasdaq. Sanifit will present at 3.00 PM on Thursday, July 19. Dr Joan Perelló, […]
Sanifit Presents Results from Phase 2 Clinical Trial of SNF472 at ERA-EDTA Congress
Palma, Spain and San Diego, USA 25th May 2018 – Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company focused on treatments for calcification disorders, announced that the results of its Phase 2 clinical trial of SNF472 were presented during an oral session earlier today at the 55th ERA-EDTA Congress taking place in Copenhagen, Denmark. The presentation […]
Latest News
UPCOMING EVENTS
11th-14th January – JPMorgan, San Francisco, USA
4th – 6th April – BIO Europe Spring, Stockholm, Sweden
27th April – 1st May – NKF Clinical Meeting, Boston, USA
21st – 24th May – ERA – EDTA, VIenna, Austria
6th – 9th June – BIO, San Francisco, USA
7th – 9th November – BIO Europe, Cologne, Germany
15th – 20th November – ASN Kidney Week, Chicago, USA